comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 17:50:23 - browse：7

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Lab trade group sues FDA to halt regulation of lab

WSS

Senators: Long

Do more moles mean more problems? Not so, says new study

How AI helped researchers track recovery from depression

Focused ultrasound for uterine fibroids: an uphill battle

Dark money group runs ads on China biotech bill

Biohaven protein

explore

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Heat waves linked to early deliveries, preterm births in new study

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CDC's new outbreak response network to include Northeastern

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Virtual Event: Putting AI to the Test

DIEP, the 'gold standard' of breast reconstruction, is under threat

Focused ultrasound for uterine fibroids: an uphill battle

As demand for Covid shots wanes, Moderna seeks its next success

Biotech lab space demand falls sharply

leisure time

Biotech stock slump in 2023: awaiting the turnaround

Addiction doctors spar with methadone clinics over legislation

Microbiome research is starting to find links to chronic diseases

Drug for rare kidney disease narrowly misses mark in clinical trial

Akili, maker of video game for ADHD, to be acquired for 34 million

What will save rural psychiatry services? Higher Medicaid payments

entertainment

leisure time

leisure time

entertainment